{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:14:08Z","timestamp":1784042048442,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s13555-024-01236-7","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T18:02:14Z","timestamp":1722276134000},"page":"2443-2455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05372653","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-0355","authenticated-orcid":false,"given":"Hidehisa","family":"Saeki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Ohya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2926-4603","authenticated-orcid":false,"given":"Hidetsugu","family":"Tsubouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"1236_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1080\/09546634.2016.1174765","volume":"27","author":"JI Silverberg","year":"2016","unstructured":"Silverberg JI, Nelson DB, Yosipovitch G. Addressing treatment challenges in atopic dermatitis with novel topical therapies. J Dermatol Treat. 2016;27:568\u201376.","journal-title":"J Dermatol Treat"},{"key":"1236_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000484407","volume":"233","author":"U Nygaard","year":"2017","unstructured":"Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233:333\u201343.","journal-title":"Dermatology"},{"key":"1236_CR3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","volume":"74","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74:491\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"10247","key":"1236_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"key":"1236_CR5","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMra074081","volume":"358","author":"T Bieber","year":"2008","unstructured":"Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483\u201394.","journal-title":"N Engl J Med"},{"key":"1236_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Delgocitinib: first approval. Drugs. 2020;80:609\u201315.","journal-title":"Drugs"},{"key":"1236_CR7","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1111\/1346-8138.15982","volume":"49","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ohya Y, Furuta J, et al. English version of clinical practice guidelines for the management of atopic dermatitis 2021. J Dermatol. 2022;49:e315\u201375.","journal-title":"J Dermatol"},{"key":"1236_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.alit.2023.04.003","volume":"73","author":"H Nakagawa","year":"2024","unstructured":"Nakagawa H, Igarashi A, Saeki H, et al. Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study. Allergol Int. 2024;73:137\u201342.","journal-title":"Allergol Int"},{"key":"1236_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1046\/j.1365-2133.2002.05006.x","volume":"147","author":"J Hanifin","year":"2002","unstructured":"Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol. 2002;147:528\u201337.","journal-title":"Br J Dermatol"},{"key":"1236_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1365-2133.2006.07538.x","volume":"156","author":"J Callen","year":"2007","unstructured":"Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007;156:203\u201321.","journal-title":"Br J Dermatol"},{"key":"1236_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1067\/mjd.2002.118337","volume":"46","author":"F Friedlander","year":"2002","unstructured":"Friedlander F, Hebert AA, Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46:387\u201393.","journal-title":"J Am Acad Dermatol"},{"key":"1236_CR12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jaci.2016.06.002","volume":"138","author":"G Egawa","year":"2016","unstructured":"Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138:350-358.e1.","journal-title":"J Allergy Clin Immunol"},{"key":"1236_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaci.2018.11.006","volume":"143","author":"AS Paller","year":"2019","unstructured":"Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143:46\u201355.","journal-title":"J Allergy Clin Immunol"},{"key":"1236_CR14","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1365-2133.2011.10449.x","volume":"165","author":"H Aubert-Wastiaux","year":"2011","unstructured":"Aubert-Wastiaux H, Moret L, Le Rhun A, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165:808\u201314.","journal-title":"Br J Dermatol"},{"key":"1236_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.123.001609","volume":"386","author":"H Hiyama","year":"2023","unstructured":"Hiyama H, Arichika N, Okada M, et al. Pharmacological profile of difamilast, a novel selective phosphodiesterase 4 inhibitor, for topical treatment of atopic dermatitis. J Pharmacol Exp Ther. 2023;386:45\u201355.","journal-title":"J Pharmacol Exp Ther"},{"key":"1236_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115195","author":"G Li","year":"2023","unstructured":"Li G, He D, Cai X, et al. Advances in the development of phosphodiesterase-4 inhibitors. Eur J Med Chem. 2023. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115195.","journal-title":"Eur J Med Chem"},{"key":"1236_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/exd.13808","volume":"28","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Hanifin JM, Boguniewicz M, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019;28:3\u201310.","journal-title":"Exp Dermatol"},{"issue":"3 Suppl 1","key":"1236_CR18","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","volume":"78","author":"R Zebda","year":"2018","unstructured":"Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018;78(3 Suppl 1):S43\u201352.","journal-title":"J Am Acad Dermatol"},{"key":"1236_CR19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/1346-8138.14979","volume":"46","author":"H Saeki","year":"2019","unstructured":"Saeki H, Kawashima M, Sugaya S, Oshiden K, Tsubouchi H. Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: a phase 2, randomized, double-blind, placebo-controlled study. J Dermatol. 2019;46:672\u20139.","journal-title":"J Dermatol"},{"key":"1236_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/1346-8138.15137","volume":"47","author":"H Saeki","year":"2019","unstructured":"Saeki H, Baba N, Oshiden K, Abe Y, Tsubouchi H. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA-15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2\u201314 years with atopic dermatitis. J Dermatol. 2019;47:17\u201324.","journal-title":"J Dermatol"},{"key":"1236_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2021.10.027","volume":"86","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ito K, Yokota D, Tsubouchi H. Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2022;86:607\u201314.","journal-title":"J Am Acad Dermatol"},{"key":"1236_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/bjd.20655","volume":"186","author":"H Saeki","year":"2022","unstructured":"Saeki H, Baba N, Ito K, Yokota D, Tsubouchi H. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial. Br J Dermatol. 2022;186:40\u20139.","journal-title":"Br J Dermatol"},{"key":"1236_CR23","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s13555-022-00751-9","volume":"12","author":"H Saeki","year":"2022","unstructured":"Saeki H, Imamura T, Yokota D, Tsubouchi H. Difamilast ointment in Japanese adult and pediatric patients with atopic dermatitis: a phase III, long-term, open-label study. Dermatol Ther (Heidelb). 2022;12:1589\u2013601.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1236_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","volume":"74","author":"M Futamura","year":"2016","unstructured":"Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of investigator global assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74:288\u201394.","journal-title":"J Am Acad Dermatol"},{"key":"1236_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10:11\u20138.","journal-title":"Exp Dermatol"},{"key":"1236_CR26","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bjd.12590","volume":"169","author":"CR Charman","year":"2013","unstructured":"Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating patient-oriented eczema measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169:1326\u201332.","journal-title":"Br J Dermatol"},{"key":"1236_CR27","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/s12519-023-00743-5","volume":"19","author":"MY Jiang","year":"2023","unstructured":"Jiang MY, Duan YP, Tong X, et al. Clinical manifestations of respiratory syncytial virus infection and the risk of wheezing and recurrent wheezing illness: a systematic review and meta-analysis. World J Pediatr. 2023;19:1030\u201340.","journal-title":"World J Pediatr"},{"key":"1236_CR28","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.rdc.2023.03.002","volume":"49","author":"M Noval Rivas","year":"2023","unstructured":"Noval Rivas M, Arditi M. Kawasaki disease and multisystem inflammatory syndrome in children: common inflammatory pathways of two distinct diseases. Rheum Dis Clin North Am. 2023;49:647\u201359.","journal-title":"Rheum Dis Clin North Am"},{"key":"1236_CR29","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jaci.2020.02.008","volume":"145","author":"T Honda","year":"2020","unstructured":"Honda T, Kabashima K. Reconciling innate and acquired immunity in atopic dermatitis. J Allergy Clin Immunol. 2020;145:1136\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"1236_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/imr.12545","volume":"278","author":"A Otsuka","year":"2017","unstructured":"Otsuka A, Nomura T, Rerknimitr P, Seidel JA, Honda T, Kabashima K. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunol Rev. 2017;278:246\u201362.","journal-title":"Immunol Rev"},{"key":"1236_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.09.272","author":"K Takahashi","year":"2023","unstructured":"Takahashi K, Miyake K, Ito J, et al. Topical application of a PDE4 inhibitor ameliorates atopic dermatitis through inhibition of basophil IL-4 production. J Invest Dermatol. 2023. https:\/\/doi.org\/10.1016\/j.jid.2023.09.272.","journal-title":"J Invest Dermatol"},{"issue":"9117","key":"1236_CR32","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(97)12082-7","volume":"351","author":"D Rudikoff","year":"1998","unstructured":"Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351(9117):1715\u201321.","journal-title":"Lancet"},{"issue":"10","key":"1236_CR33","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0165-5876(03)00203-9","volume":"67","author":"I Brook","year":"2003","unstructured":"Brook I. Microbial dynamics of purulent nasopharyngitis in children. Int J Pediatr Otorhinolaryngol. 2003;67(10):1047\u201353.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"1236_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12016-018-8711-2","volume":"56","author":"J Borok","year":"2019","unstructured":"Borok J, Matiz C, Goldenberg A, Jacob SE. Contact dermatitis in atopic dermatitis children\u2014past, present, and future. Clin Rev Allergy Immunol. 2019;56:86\u201398.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1236_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000529026","volume":"120","author":"J Marissen","year":"2023","unstructured":"Marissen J, Gomez de Ag\u00fcero M, Chandorkar P, et al. The delicate skin of preterm infants: barrier function, immune-microbiome interaction, and clinical implications. Neonatology. 2023;120:295\u2013307.","journal-title":"Neonatology"},{"key":"1236_CR36","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1365-2133.2005.06592.x","volume":"152","author":"S Reitamo","year":"2005","unstructured":"Reitamo S, Ortonne JP, Sand C, et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152:1282\u20139.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01236-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01236-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01236-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T12:42:07Z","timestamp":1726144927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01236-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1236"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01236-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hidehisa Saeki received grants from AbbVie, Eisai Co., Ltd., LEO Pharma K.K., Maruho Co., Ltd., Taiho Pharmaceutical Co., Ltd., Torii Pharmaceutical Co., Ltd., and Tokiwa Pharmaceutical Co., Ltd., and honoraria from AbbVie, Eli Lilly Japan K.K., Japan Tobacco Inc., LEO Pharma K.K., Maruho Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Taiho Pharmaceutical Co., Ltd., Pfizer Japan Inc., Amgen Inc., and Torii Pharmaceutical Co., Ltd. Yukihiro Ohya received grants from Fam Pharma, Kao, and Maruho Co., Ltd., consulting fees from AbbVie, Eli Lilly Japan K.K., LEO Pharma K. K., Maruho Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Sanofi K.K., and honoraria from AbbVie, Mitsubishi Tanabe Pharma Corporation, Pfizer, Pola Pharma Inc., Sanofi K.K., Sinopharm, Taiho Pharmaceutical Co., Ltd., Thermo Fisher Scientific, and Torii Pharmaceutical Co., Ltd. Naoko Baba received honoraria from Otsuka Pharmaceutical Co., Ltd., Maruho Co., Ltd., and Torii Pharmaceutical Co., Ltd. Tomomi Imamura, Daisuke Yokota, Hidetsugu Tsubouchi, Toshiya Oka, Tomoyo Takayama, Ayaka Soga, Yu Takeuchi, Daisaku Michikami, Takahiro Tsuchiya, and Hiroe Takeda are employees of Otsuka Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study received approval by the respective institutional review boards at study sites and was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and the applicable local laws and regulatory requirements in Japan. Parents or guardians of all infants provided written informed consents before participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}